HighField Biopharma's ASCO 2024 Poster Shows HFK1 Immunoliposome May Surpass Antibody Drug Conjugates

Hangzhou, China—HighField Biopharmaceuticals, a clinical-stage company specializing in lipid-based therapies for cancer, diabetes, and other diseases, is set to present promising clinical and preclinical results of their groundbreaking drug HFK1 at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 31 to June 4.

HFK1 is an innovative drug encapsulated in immunoliposomes designed for the treatment of solid tumors with HER2 low expression. The poster presentation at ASCO will highlight early findings from HighField's Phase 1a study on HFK1. One notable case involves a patient with lung metastasis from a rare HER2 low cancer, who has been on HFK1 treatment for over five months without dose-limiting toxicity and has shown stable disease.

The data, presented by HighField's CEO and Scientific Founder Dr. Yuhong Xu, will include comparative studies between HFK1, other antibody drug conjugates (ADCs), and PEGylated liposomal doxorubicin (PLD). The results indicate that HFK1 significantly enhances safety and efficacy compared to ADCs and PLD. Remarkably, HFK1 has outperformed ADCs in widening the therapeutic window and curbing tumor growth.

Dr. Xu expressed optimism about the upcoming presentation, stating, "We are eager to share the positive results of our HFK1 studies at ASCO. These findings reinforce our belief that our unique drug encapsulated immunoliposomes provide a novel option for targeting HER2 low cancers with fewer off-target toxicities and broader therapeutic windows."

The poster, titled "The design, preclinical study and Phase 1 dose escalation of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment," will be displayed on Saturday, June 1, 2024, from 9 am to 12 pm CDT.

HighField's Phase 1 open-label clinical trial is currently recruiting patients with advanced refractory solid tumors that exhibit HER2 low expression. Phase 1a involves dose escalation, which will be followed by a Phase 1b dose expansion phase. Both phases aim to assess the safety and initial efficacy of HFK1. Additional information can be found on clinicaltrials.gov under the identifier NCT05861895.

HighField’s immunoliposomes signify a new era in targeted chemotherapy, building on the success of antibody drug conjugates (ADCs). Thanks to their distinct characteristics, these immunoliposomes may offer improved safety and efficacy across a wide range of solid tumor types.

About HighField Biopharmaceuticals

HighField Biopharmaceuticals is a clinical-stage company focused on innovative liposome constructs aimed at transforming existing immuno-oncology and other disease treatment technologies. Their facilities include a research and development center and a GMP-compliant production site. HighField’s leading clinical program, HF1K16, involves a drug encapsulated immune-modulating liposome containing all-trans retinoic acid, targeting myeloid-derived suppressor cells for solid tumor treatment. The company's pipeline also features drug encapsulated immunoliposomes for various solid tumor cancers and lipid therapies for gene delivery and gene therapy.